Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain

INTRODUCTION: Glucagon-like peptide-1 (GLP-1) receptor agonists are used successfully in the treatment of patients with type 2 diabetes as they are associated with low hypoglycemia rates, weight loss and improved glycemic control. This study compared, in the Spanish setting, the cost-effectiveness o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mezquita-Raya, Pedro, Ramírez de Arellano, Antonio, Kragh, Nana, Vega-Hernandez, Gabriela, Pöhlmann, Johannes, Valentine, William J., Hunt, Barnaby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380501/
https://www.ncbi.nlm.nih.gov/pubmed/28224463
http://dx.doi.org/10.1007/s13300-017-0239-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380501/
https://www.ncbi.nlm.nih.gov/pubmed/28224463
http://dx.doi.org/10.1007/s13300-017-0239-6

Ejemplares similares